Ataluren: A 'no-nonsense' approach for pulmonary diseases

Pulmonary Pharmacology and Therapeutics

Volumn 26, Issue 3, 2013, Pages 398-399

  Loudon, John A ^a  

^a Wetherill Park Medical Centre   (Australia)

Author keywords

Ataluren; Cystic fibrosis; Lung carcinoma; Muscular dystyrophy; Nonsense mutation; Readthrough; Thalassemia; Tumor suppressor gene

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; APC PROTEIN; ATALUREN; ATM PROTEIN; NF1 PROTEIN; PROTEIN; PROTEIN P53; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CELL VIABILITY; CYSTIC FIBROSIS; DUCHENNE MUSCULAR DYSTROPHY; HUMAN; LETTER; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG DISEASE; LUNG NON SMALL CELL CANCER; MISSENSE MUTATION; NONSENSE MUTATION; ONCOGENE; PERSONALIZED MEDICINE; PHENOTYPE; PREMATURE TERMINATION CODON; PRIORITY JOURNAL; RIBOSOME; SOMATIC MUTATION; STOP CODON; THALASSEMIA; TUMOR SUPPRESSOR GENE;

CODON, NONSENSE; GENES, P53; HUMANS; LUNG DISEASES; LUNG NEOPLASMS; OXADIAZOLES; PHENOTYPE;

EID: 84875956919     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2013.01.007     Document Type: Letter

References (9)

1. Lee H.L., Dougherty J.P. Pharmaceutical therapies to recode nonsense mutations in inherited diseases. Pharmacol Ther 2012, 136:227-266.
2. Loudon J.A. Cancer: a novel "no-nonsense" approach to treatment. Oncol Res 2010, 19:55-66.
3. Chebbo A., Tfaili A., Jones S.F. Hypoventilation syndromes. Med Clin North Am 2011, 95:1189-1202.
4. Vij R., Machado R.F. Pulmonary complications of hemoglobinopathies. Chest 2010, 138:973-983.
5. Bordeira-Carriço R., Pêgo A.P., Santos M., Oliveira C. Cancer syndromes and therapy by stop-codon readthrough. Trends Mol Med 2012, 18:667-678.
6. Hashimoto T., Tokuchi Y., Hayashi M., Kobayashi Y., Nishida K., Hayashi S., et al. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas. Cancer Res 1999, 59:5572-5577.
7. Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
8. Floquet C., Deforges J., Rousset J.P., Bidou L. Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides. Nucleic Acids Res 2011, 39:3350-3362.
9. Loudon J.A. Ataluren: time for a 'no-nonsense' approach to heart diseases. Cardiovasc Drugs Ther 2013 Jan 6, 10.1007/s10557-012-6435-8.